Live
FierceBiotech'Biopharma ecosystem is back to full health,' fueled by M&A: PwCFierceBiotechJazz, AbCellera strike TCE discovery and development deal worth up to $792M per drugEndpoints NewsJazz turns to AbCellera for T cell engagers in up to $4.1B partnershipEndpoints NewsSpot Bio launches with $40M to study mRNA therapy for muscular dystrophyEndpoints NewsTriveni Bio raises $65M ahead of upcoming readouts on eczema drugsCellCellular architecture and neighborhood-informed virtual spatial tumor profiling from histopathologyCellA CRISPR knockout mouse library for functional genomics in influenza researchEndpoints NewsMigraine biotech Vedana Therapeutics makes its debut with $46M Series ABioPharma DiveA new Westlake-backed biotech takes aim at migraineseLifeCorrection: The myeloid cell-driven transdifferentiation of endothelial cells into pericytes promotes the restoration of BBB function and brain self-repair after stroke10x Genomics NewsTXG (Nasdaq) RSU vesting entries listed on Form 144 with JP Morgan intermediary - Stock TitanClinical OMICsCancer Diagnostics: Droplet Digital PCR Testing for HPV+ Cancer in the Clinic
Endpoints News Jan 28, 2026

Round three of IRA negotiations is expected to be ‘manageable’ for pharma

Round three of IRA negotiations is expected to be ‘manageable’ for pharma

Original
Body unavailable. Use the original source.